Navigation Links
New study finds uncontrollable stress worsens symptoms of endometriosis
Date:4/7/2008

SAN DIEGO, CA Endometriosis is a poorly understood condition that incapacitates and affects the productivity and lifestyle of millions of women around the world. In the US, it affects approximately six million women and adolescents at a cost of some $1.6 billion per year. It is a chronic painful disease which occurs when endometrial tissue grows as lesions outside the uterus, mainly in the area of the ovaries and fallopian tubes, but can also affect the intestinal tract. The condition results in chronic pelvic pain, painful menstrual periods and pain during intercourse.

Many patients report suffering from high levels of stress due to the impact that painful symptoms have on all aspects of their life, including work, family and personal relationships. For example, the physical pain they experience during intercourse can disrupt a healthy sexual relationship, thus causing anguish and discord which leads to further stress.

Circumstantial evidence suggests that a variety of stress management techniques can help women handle stressful situations related to the disease. However, it is not yet known whether stress affects the prevalence or progression of the disease.

A new study investigating the relationship between stress and the painful symptoms of the disease is currently underway. It offers, for the first time, evidence of the negative consequences of stress in the progression of endometriosis, most likely through an effect on the immune system.

Presentation at the 121st Annual Meeting of the American Physiological Society

The study was conducted by an interdisciplinary team of investigators with expertise in endometriosis, animal physiology and behavior. Marielly Cuevas, Olga I. Santiago, Kenira J. Thompson and Caroline B. Appleyard, Department of Physiology and Pharmacology, Ponce School of Medicine, Ponce, Puerto Rico, and Idhaliz Flores of the Department of Microbiology. Dr. Appleyard and her graduate stud
'/>"/>

Contact: Donna Krupa
DKrupa@the-aps.org
619-525-6202
American Physiological Society
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals
2. A study by the MUHC and McGill University opens a new door to understanding cancer
3. Study begins to reveal clues to the cause and progression of sepsis
4. Clones on task serve greater good, evolutionary study shows
5. New study warns limited carbon market puts 20 percent of tropical forest at risk
6. New study examines how rearing environment can alter navigation
7. Study links cat disease to flame retardants in furniture and to pet food
8. New continent and species discovered in Atlantic study
9. Study shows link between alcohol consumption and hiv disease progression
10. Feeling hot, hot, hot: New study suggests ways to control fever-induced seizures
11. Study finds environmental tests help predict hospital-acquired Legionnaires disease risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)...  HITLAB SM announced today its completion ... confirm its adherence to current U.S. Food and ... to conduct regulated smart device and smart phone ... safety and research quality. "HITLAB is ... delivery with innovative technology," said Laura Pugliese ...
(Date:12/15/2014)... 2014 Research and Markets ( ... "Global Facial Recognition Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is a ... recognition system measures the overall facial feature of ... and the distance between eyes. Facial recognition is ...
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences International ... has released a new series of digital telemetry ... toxicology researchers. M series, part of the PhysioTel™ ... the best possible physiologic data when incorporating functional ... functional endpoints to toxicology studies has evolved from ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3New telemetry implants expected to change how large animal toxicology studies are conducted 2
... is a metaphorical example of the perfect invasion by a ... a deserted island in the Galapagos Archipelago, the first cancer ... through many generations to establish itself as an invader of ... like any newly stabilized species in different ecological niches, cancer ...
... at Pacific Northwest National Laboratory have developed a ... meet or exceed current and emerging defense and ... Quartz Laser Photo-Acoustic Sensing, or "QPAS," is now ... PNNL, a Department of Energy national laboratory, has ...
... blood pressure measuring above the normal range (less than 120/80 ... strokes, or kidney disease. Lifestyle changes are the first-stage treatment ... , Many patients with high blood ... In so doing, many have consumed danshen, a Chinese herb ...
Cached Biology News:Cancer that colonizes our bodies 2New sensor detects gaseous chemical weapon surrogates in 45 seconds 2Active ingredient in common Chinese herb shown to reduce hypertension 2
(Date:12/17/2014)... 2014 Gene synthesis and bioengineering ... entered into a technology access and services agreement ... DNA2.0’s proprietary protein engineering technology, known as “ProteinGPS®” ... are extremely excited that the global leader ADM ... proprietary bioengineering technology has now been validated through ...
(Date:12/17/2014)... CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... primary commercial focus on China , ... C meeting with the U.S. Food and Drug Administration ... February 2015.  During this meeting the Company will seek ...
(Date:12/15/2014)... & PETACH TIKVAH, Israel , Dec. ... BCLI ), a leading developer of adult stem ... subsidiary Brainstorm Cell Therapeutics Ltd. was awarded a grant ... Office of the Chief Scientist (OCS).  This is ... of grant support from the Office of the Chief ...
(Date:12/15/2014)...  Ascendis Pharma A/S, a biotechnology company that ... unmet medical needs, today announced positive six-month interim ... to evaluate once-weekly TransCon Growth Hormone in children ... analysis consists of 25 patients, representing approximately 50% ... completing all six months of treatment. ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4
... Biofuels Key Issues in 2008, NEW YORK, Dec. ... and developments in biofuels are some of the issues,addressed ... The Outlook is produced annually by the Food ... analysis covering all of,the major sectors throughout the food ...
... Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) has completed patient ... investigating the intratumoural,delivery of REOLYSIN(R) in combination ... A total of 23 patients received a ... REOLYSIN(R) at escalating dosages up to a,maximum ...
... Pharmaceuticals,LLC, a clinical stage drug-development company commercializing,first-in-class ... that enhances,oxygen diffusion, today announced that one ... recently recognized as a co-inventor of the ... alpha), a,erythropoiesis stimulating agent (US Patent No. ...
Cached Biology Technology:Rabobank Releases Annual North American Food & Agribusiness Outlook 2Rabobank Releases Annual North American Food & Agribusiness Outlook 3Rabobank Releases Annual North American Food & Agribusiness Outlook 4Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial 2Co-Inventor of Amgen's Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals' First-in-Class Oxygen Enhancing Therapeutics 2
Phospho-4E-BP1 (Thr37/46) (236B4) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
Phospho-TAK1 (Thr184/187) (90C7) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
... polyclonal to MSY2/YBOX2 ( Abpromise ... Antigen: Synthetic peptide derived ... C-terminus of Human MSY2/YBOX2. (Note: ... (Peptide available as ...
SAPK/JNK Antibody...
Biology Products: